Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

38.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 Next >
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. 
Via Benzinga
Where Ionis Pharmaceuticals Stands With Analysts
Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Recap: Ionis Pharmaceuticals Q1 Earnings
Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Expert Ratings For Ionis Pharmaceuticals
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, trader! It's time to start off Friday with a breakdown of the biggest pre-market stock movers traders need to know about! 
Via InvestorPlace
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Ionis Reveals Positive Results From Anti-Blood Clot Therapy In Hemodialysis
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced positive topline results of the Phase 2b clinical trial of fesomersen in patients with end-stage renal disease (ESRD) on hemodialysis. 
Via Benzinga
FDA Accepts Biogen's Submission For Neurodegenerative Disease Drug Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted Biogen’s (NASDAQ: BIIB) New Drug Application (NDA) for its lead asset Tofersen for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis... 
Via Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Undervalued Biotech Stocks to Buy Before They Boom
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. 
Via InvestorPlace
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
  
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
Cathie Wood's Ark Invest Sheds $35M In 3D Printing Company Stratasys — What It Bought Instead
As the market reopened following the long July 4 weekend, Cathie Wood-run Ark Invest made some portfolio moves, notable among which is the offloading of a huge chunk of Stratasys Ltd. (NASDAQ: SSYS)... 
Via Benzinga
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors. 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial
Via Benzinga
5 Cathie Wood Stocks to Buy in June
These are the five best Cathie Wood stocks to buy in June. EXAS, IONS, KTOS, TRMB, and PATH can make excellent investments. 
Via InvestorPlace
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves? 
Via InvestorPlace
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter. 
Via Benzinga
What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings: 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
How To Attend Ionis Pharmaceuticals Q1 2022 Earnings Conference Call
Ionis Pharmaceuticals (NASDAQ:IONS) will host a conference call at 11:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol
Ionis Pharmaceuticals Inc (NASDAQ: IONS) and its partner, AstraZeneca Plc (NASDAQ: AZN), have  
Via Benzinga
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week. 
Via Investor's Business Daily
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have  
Via Benzinga
Why Cramer Likes Ferguson And Stanley Black & Decker
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) is a "momentum-driven stock" whose momentum he... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.